<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title>Cardiovascular Diabetology</journal-title><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17316429</article-id><article-id pub-id-type="pmc">1819366</article-id><article-id pub-id-type="publisher-id">1475-2840-6-8</article-id><article-id pub-id-type="doi">10.1186/1475-2840-6-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Pro-oxidant effect of α-tocopherol in patients with Type 2 Diabetes after an oral glucose tolerance test – a randomised controlled trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Winterbone</surname><given-names>Mark S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mark.winterbone@bbsrc.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Sampson</surname><given-names>Mike J</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>mike.sampson@nnuh.nhs.uk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Saha</surname><given-names>Shikha</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>shikha.saha@bbsrc.ac.uk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Hughes</surname><given-names>Jackie C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jackie.brown@bbsrc.ac.uk</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hughes</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>davida.hughes@bbsrc.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Food Research, Norwich Research Park, Norwich, NR4 7UA, UK</aff><aff id="I2"><label>2</label>Bertram Diabetes Research Unit, Norfolk &amp; Norwich University Hospital NHS Trust, Norwich, NR4 7UY, UK</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>22</day><month>2</month><year>2007</year></pub-date><volume>6</volume><fpage>8</fpage><lpage>8</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiab.com/content/6/1/8"></ext-link><history><date date-type="received"><day>19</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2007</year></date></history><permissions><copyright-statement>Copyright © 2007 Winterbone et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Winterbone et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3422" xml_f="3432" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3443" xml_f="3702" txt_i="22" txt_f="281">As a part of a larger study investigating the effects of α-tocopherol on gene expression in type 2 diabetics we observed a pro-oxidant effect of α-tocopherol which we believe may be useful in interpreting outcomes of large intervention trials of α-tocopherol.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3743" xml_f="3750" txt_i="283" txt_f="290">Methods</offsets></title><p><offsets xml_i="3761" xml_f="4057" txt_i="291" txt_f="587">19 type 2 diabetes subjects were randomised into two groups taking either 1200 IU/day of α-tocopherol or a matched placebo for 4 weeks. On day 0 and 29 of this study oxidative DNA damage was assessed in mononuclear cells from fasted blood samples and following a 2 h glucose tolerance test (GTT).</offsets></p></sec><sec><title><offsets xml_i="4079" xml_f="4086" txt_i="589" txt_f="596">Results</offsets></title><p><offsets xml_i="4097" xml_f="4421" txt_i="597" txt_f="921">On day 0 there was no significant difference in oxidative DNA damage between the two groups or following a GTT. On day 29 there was no significant difference in oxidative DNA damage in fasted blood samples, however following a GTT there was a significant increase in oxidative DNA damage in the α-tocopherol treatment group.</offsets></p></sec><sec><title><offsets xml_i="4443" xml_f="4453" txt_i="923" txt_f="933">Conclusion</offsets></title><p><offsets xml_i="4464" xml_f="4628" txt_i="934" txt_f="1098">High dose supplementation with α-tocopherol primes mononuclear cells from patients with type 2 diabetes for a potentially damaging response to acute hyperglycaemia.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="4690" xml_f="4700" txt_i="1107" txt_f="1117">Background</offsets></title><p><offsets xml_i="4711" xml_f="4943" txt_i="1118" txt_f="1350">Type 2 diabetes is associated with an increased risk of atherosclerosis. Increased oxidative stress and damage to lipoproteins, cell membrane components and chromosomal DNA may play a role in this increased risk of atherosclerosis [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="4974" xml_f="4975" txt_i="1350" txt_f="1351">1</offsets></xref><offsets xml_i="4982" xml_f="4983" txt_i="1351" txt_f="1352">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5014" xml_f="5015" txt_i="1352" txt_f="1353">2</offsets></xref><offsets xml_i="5022" xml_f="5112" txt_i="1353" txt_f="1443">]. Increased susceptibility to oxidative DNA damage has been reported in type 2 diabetes [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5143" xml_f="5144" txt_i="1443" txt_f="1444">3</offsets></xref><offsets xml_i="5151" xml_f="5152" txt_i="1444" txt_f="1445">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5183" xml_f="5184" txt_i="1445" txt_f="1446">4</offsets></xref><offsets xml_i="5191" xml_f="5349" txt_i="1446" txt_f="1604">], and we have shown recently an inverse relationship between oxidative DNA damage and telomere length in blood monocytes from patients with type 2 diabetes [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="5380" xml_f="5381" txt_i="1604" txt_f="1605">5</offsets></xref><offsets xml_i="5388" xml_f="5652" txt_i="1605" txt_f="1869">]. The potential role of oxidative stress in atherogenesis made antioxidant interventions appealing as a vascular risk reduction strategy, but there has subsequently been a lack of evidence of improved vascular outcomes in large scale antioxidant clinical trials [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5683" xml_f="5684" txt_i="1869" txt_f="1870">6</offsets></xref><offsets xml_i="5691" xml_f="5692" txt_i="1870" txt_f="1871">,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5723" xml_f="5724" txt_i="1871" txt_f="1872">7</offsets></xref><offsets xml_i="5731" xml_f="5849" txt_i="1872" txt_f="1990">]. A recent meta-analysis has also suggested an increased risk of all-cause mortality from vitamin E supplementation [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="5880" xml_f="5881" txt_i="1990" txt_f="1991">8</offsets></xref><offsets xml_i="5888" xml_f="5954" txt_i="1991" txt_f="2057">]. Potential reasons for this lack of benefit have been reviewed [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="5985" xml_f="5986" txt_i="2057" txt_f="2058">9</offsets></xref><offsets xml_i="5993" xml_f="6130" txt_i="2058" txt_f="2195">], as has the possible pro-oxidant effect of antioxidants in disease processes with existing high background levels of oxidative stress [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6162" xml_f="6164" txt_i="2195" txt_f="2197">10</offsets></xref><offsets xml_i="6171" xml_f="6173" txt_i="2197" txt_f="2199">].</offsets></p><p><offsets xml_i="6180" xml_f="6551" txt_i="2200" txt_f="2571">In this report we show an increase in oxidative DNA damage in mononuclear cells from patients with type 2 diabetes who had been supplemented with 1200 IU/d α-tocopherol, following a glucose tolerance test. This level of supplementation was chosen as we previously have shown no effect on DNA strand breaks or oxidisability with a lower dose of 400 IU α-tocopherol daily [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6582" xml_f="6583" txt_i="2571" txt_f="2572">3</offsets></xref><offsets xml_i="6590" xml_f="6684" txt_i="2572" txt_f="2666">], but higher doses have shown a reduction in DNA single strand breaks using the comet assay [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6716" xml_f="6718" txt_i="2666" txt_f="2668">11</offsets></xref><offsets xml_i="6725" xml_f="6727" txt_i="2668" txt_f="2670">].</offsets></p></sec><sec><title><offsets xml_i="6749" xml_f="6769" txt_i="2672" txt_f="2692">Subjects and Methods</offsets></title><sec><title><offsets xml_i="6789" xml_f="6797" txt_i="2693" txt_f="2701">Subjects</offsets></title><p><offsets xml_i="6808" xml_f="7737" txt_i="2702" txt_f="3631">All subjects gave written informed consent which was approved by the local ethics committee. We studied 19 subjects with type 2 diabetes, all Caucasian males between 50 and 65 years, who were recruited if they were non smokers, not taking dietary supplements, had never received gliclazide, antihypertensives, or angiotensin converting enzyme inhibitors, which have antioxidant or anti-inflammatory properties. Subjects were treated with diet alone (n = 5), metformin alone (n = 3), sulphonylureas alone (n = 4), metformin and sulphonylureas in combination (n = 3), and insulin alone or in combination with metformin (n = 4). Thirteen of the 19 subjects were taking an HMG CoA reductase inhibitor ('statin'). The volunteers were randomised into two groups, taking either 1200 IU α-tocopherol/d (n = 10) or matching placebo (n = 9) for 4 weeks. Compliance was monitored by pill count and plasma α-tocopherol concentrations. Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="7769" xml_f="7770" txt_i="3631" txt_f="3632">1</offsets></xref><offsets xml_i="7777" xml_f="7829" txt_i="3632" txt_f="3684"> summarises the clinical features of the two groups.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="7877" xml_f="7884" txt_i="3685" txt_f="3692">Table 1</offsets></label><caption><p><offsets xml_i="7904" xml_f="8020" txt_i="3692" txt_f="3808">Clinical and biochemical data groups in type 2 diabetes treated with 1200 IU α-tocopherol/day or placebo for 4 weeks</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><offsets xml_i="8120" xml_f="8147" txt_i="3810" txt_f="3837">α-tocopherol Group (n = 10)</offsets></td><td align="left" colspan="2"><offsets xml_i="8181" xml_f="8202" txt_i="3838" txt_f="3859">Placebo Group (n = 9)</offsets></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="left"><offsets xml_i="8290" xml_f="8295" txt_i="3863" txt_f="3868">Day 0</offsets></td><td align="left"><offsets xml_i="8317" xml_f="8323" txt_i="3869" txt_f="3875">Day 29</offsets></td><td align="left"><offsets xml_i="8345" xml_f="8350" txt_i="3876" txt_f="3881">Day 0</offsets></td><td align="left"><offsets xml_i="8372" xml_f="8378" txt_i="3882" txt_f="3888">Day 29</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="8424" xml_f="8431" txt_i="3889" txt_f="3896">Age (Y)</offsets></td><td align="left"><offsets xml_i="8453" xml_f="8464" txt_i="3897" txt_f="3908">62.7 (1.81)</offsets></td><td align="left"><offsets xml_i="8486" xml_f="8488" txt_i="3909" txt_f="3911">__</offsets></td><td align="left"><offsets xml_i="8510" xml_f="8521" txt_i="3912" txt_f="3923">61.9 (1.92)</offsets></td><td align="left"><offsets xml_i="8543" xml_f="8545" txt_i="3924" txt_f="3926">__</offsets></td></tr><tr><td align="left"><offsets xml_i="8576" xml_f="8593" txt_i="3927" txt_f="3944">Diabetes duration</offsets></td><td align="left"><offsets xml_i="8615" xml_f="8626" txt_i="3945" txt_f="3956">11.1 (2.52)</offsets></td><td align="left"><offsets xml_i="8648" xml_f="8650" txt_i="3957" txt_f="3959">__</offsets></td><td align="left"><offsets xml_i="8672" xml_f="8681" txt_i="3960" txt_f="3969">2.6 (0.4)</offsets><sup><offsets xml_i="8686" xml_f="8687" txt_i="3969" txt_f="3970">a</offsets></sup></td><td align="left"><offsets xml_i="8715" xml_f="8717" txt_i="3971" txt_f="3973">__</offsets></td></tr><tr><td align="left"><offsets xml_i="8748" xml_f="8751" txt_i="3974" txt_f="3977">BMI</offsets></td><td align="left"><offsets xml_i="8773" xml_f="8783" txt_i="3978" txt_f="3988">29.9 (1.2)</offsets></td><td align="left"><offsets xml_i="8805" xml_f="8807" txt_i="3989" txt_f="3991">__</offsets></td><td align="left"><offsets xml_i="8829" xml_f="8839" txt_i="3992" txt_f="4002">29.4 (1.3)</offsets></td><td align="left"><offsets xml_i="8861" xml_f="8863" txt_i="4003" txt_f="4005">__</offsets></td></tr><tr><td align="left"><offsets xml_i="8894" xml_f="8897" txt_i="4006" txt_f="4009">WHR</offsets></td><td align="left"><offsets xml_i="8919" xml_f="8931" txt_i="4010" txt_f="4022">0.92 (0.026)</offsets></td><td align="left"><offsets xml_i="8953" xml_f="8955" txt_i="4023" txt_f="4025">__</offsets></td><td align="left"><offsets xml_i="8977" xml_f="8989" txt_i="4026" txt_f="4038">0.94 (0.021)</offsets></td><td align="left"><offsets xml_i="9011" xml_f="9013" txt_i="4039" txt_f="4041">__</offsets></td></tr><tr><td align="left"><offsets xml_i="9044" xml_f="9075" txt_i="4042" txt_f="4073">Fasting plasma glucose (mmol/L)</offsets></td><td align="left"><offsets xml_i="9097" xml_f="9108" txt_i="4074" txt_f="4085">10.7 (0.94)</offsets></td><td align="left"><offsets xml_i="9130" xml_f="9141" txt_i="4086" txt_f="4097">10.2 (0.86)</offsets></td><td align="left"><offsets xml_i="9163" xml_f="9173" txt_i="4098" txt_f="4108">7.6 (0.39)</offsets><sup><offsets xml_i="9178" xml_f="9179" txt_i="4108" txt_f="4109">a</offsets></sup></td><td align="left"><offsets xml_i="9207" xml_f="9217" txt_i="4110" txt_f="4120">7.7 (0.41)</offsets><sup><offsets xml_i="9222" xml_f="9223" txt_i="4120" txt_f="4121">b</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="9260" xml_f="9289" txt_i="4122" txt_f="4151">Fasting plasma insulin (mU/L)</offsets></td><td align="left"><offsets xml_i="9311" xml_f="9322" txt_i="4152" txt_f="4163">49.6 (6.67)</offsets></td><td align="left"><offsets xml_i="9344" xml_f="9355" txt_i="4164" txt_f="4175">56.2 (9.91)</offsets></td><td align="left"><offsets xml_i="9377" xml_f="9388" txt_i="4176" txt_f="4187">55.5 (7.81)</offsets></td><td align="left"><offsets xml_i="9410" xml_f="9421" txt_i="4188" txt_f="4199">54.5 (6.87)</offsets></td></tr><tr><td align="left"><offsets xml_i="9452" xml_f="9484" txt_i="4200" txt_f="4232">Post-GTT plasma glucose (mmol/L)</offsets></td><td align="left"><offsets xml_i="9506" xml_f="9517" txt_i="4233" txt_f="4244">20.2 (1.25)</offsets><sup><offsets xml_i="9522" xml_f="9523" txt_i="4244" txt_f="4245">c</offsets></sup></td><td align="left"><offsets xml_i="9551" xml_f="9562" txt_i="4246" txt_f="4257">19.1 (1.26)</offsets><sup><offsets xml_i="9567" xml_f="9568" txt_i="4257" txt_f="4258">c</offsets></sup></td><td align="left"><offsets xml_i="9596" xml_f="9607" txt_i="4259" txt_f="4270">15.1 (0.94)</offsets><sup><offsets xml_i="9612" xml_f="9613" txt_i="4270" txt_f="4271">c</offsets></sup></td><td align="left"><offsets xml_i="9641" xml_f="9652" txt_i="4272" txt_f="4283">15.0 (1.32)</offsets><sup><offsets xml_i="9657" xml_f="9658" txt_i="4283" txt_f="4284">c</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="9695" xml_f="9725" txt_i="4285" txt_f="4315">Post-GTT plasma insulin (mU/L)</offsets></td><td align="left"><offsets xml_i="9747" xml_f="9757" txt_i="4316" txt_f="4326">135 (37.1)</offsets><sup><offsets xml_i="9762" xml_f="9763" txt_i="4326" txt_f="4327">d</offsets></sup></td><td align="left"><offsets xml_i="9791" xml_f="9801" txt_i="4328" txt_f="4338">124 (31.9)</offsets><sup><offsets xml_i="9806" xml_f="9807" txt_i="4338" txt_f="4339">d</offsets></sup></td><td align="left"><offsets xml_i="9835" xml_f="9845" txt_i="4340" txt_f="4350">218 (47.7)</offsets><sup><offsets xml_i="9850" xml_f="9851" txt_i="4350" txt_f="4351">c</offsets></sup></td><td align="left"><offsets xml_i="9879" xml_f="9889" txt_i="4352" txt_f="4362">261 (87.0)</offsets><sup><offsets xml_i="9894" xml_f="9895" txt_i="4362" txt_f="4363">d</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="9932" xml_f="9941" txt_i="4364" txt_f="4373">HbA1c (%)</offsets></td><td align="left"><offsets xml_i="9963" xml_f="9972" txt_i="4374" txt_f="4383">8.4 (0.6)</offsets></td><td align="left"><offsets xml_i="9994" xml_f="9996" txt_i="4384" txt_f="4386">__</offsets></td><td align="left"><offsets xml_i="10018" xml_f="10027" txt_i="4387" txt_f="4396">7.2 (0.3)</offsets></td><td align="left"><offsets xml_i="10049" xml_f="10051" txt_i="4397" txt_f="4399">__</offsets></td></tr><tr><td align="left"><offsets xml_i="10082" xml_f="10110" txt_i="4400" txt_f="4428">Plasma α-tocopherol (μmol/L)</offsets></td><td align="left"><offsets xml_i="10132" xml_f="10143" txt_i="4429" txt_f="4440">28.9 (1.82)</offsets></td><td align="left"><offsets xml_i="10165" xml_f="10176" txt_i="4441" txt_f="4452">66.5 (7.26)</offsets><sup><offsets xml_i="10181" xml_f="10182" txt_i="4452" txt_f="4453">e</offsets></sup></td><td align="left"><offsets xml_i="10210" xml_f="10221" txt_i="4454" txt_f="4465">24.4 (1.71)</offsets></td><td align="left"><offsets xml_i="10243" xml_f="10254" txt_i="4466" txt_f="4477">25.0 (1.78)</offsets></td></tr><tr><td align="left"><offsets xml_i="10285" xml_f="10316" txt_i="4478" txt_f="4509">8-oxoquanine fluorescence (MFI)</offsets></td><td align="left"><offsets xml_i="10338" xml_f="10348" txt_i="4510" txt_f="4520">462 (28.0)</offsets></td><td align="left"><offsets xml_i="10370" xml_f="10380" txt_i="4521" txt_f="4531">456 (19.0)</offsets></td><td align="left"><offsets xml_i="10402" xml_f="10412" txt_i="4532" txt_f="4542">506 (27.1)</offsets></td><td align="left"><offsets xml_i="10434" xml_f="10444" txt_i="4543" txt_f="4553">495 (15.2)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="10490" xml_f="10515" txt_i="4554" txt_f="4579">Data shown are means (SE)</offsets></p><p><sup><offsets xml_i="10527" xml_f="10529" txt_i="4580" txt_f="4582">a </offsets></sup><offsets xml_i="10535" xml_f="10571" txt_i="4582" txt_f="4615">p &lt; 0.01 placebo v α-tocopherol; </offsets><sup><offsets xml_i="10576" xml_f="10578" txt_i="4615" txt_f="4617">b </offsets></sup><offsets xml_i="10584" xml_f="10619" txt_i="4617" txt_f="4649">p &lt; 0.05 placebo v α-tocopherol;</offsets></p><p><sup><offsets xml_i="10631" xml_f="10633" txt_i="4650" txt_f="4652">c </offsets></sup><offsets xml_i="10639" xml_f="10671" txt_i="4652" txt_f="4681">p &lt; 0.01 Fasting v post-GTT; </offsets><sup><offsets xml_i="10676" xml_f="10678" txt_i="4681" txt_f="4683">d </offsets></sup><offsets xml_i="10684" xml_f="10714" txt_i="4683" txt_f="4710">p &lt; 0.05 Fasting v post-GTT</offsets></p><p><sup><offsets xml_i="10726" xml_f="10728" txt_i="4711" txt_f="4713">e </offsets></sup><offsets xml_i="10734" xml_f="10760" txt_i="4713" txt_f="4736">p &lt; 0.01 Day 0 v Day 29</offsets></p></table-wrap-foot></table-wrap></sec><sec sec-type="materials"><title><offsets xml_i="10834" xml_f="10843" txt_i="4738" txt_f="4747">Materials</offsets></title><p><offsets xml_i="10854" xml_f="11325" txt_i="4748" txt_f="5219">On day 0 and day 29 of the study fasting blood samples were collected into vacutainer CPT tubes (Becton Dickinson, Oxford, UK). Volunteers were given a standard oral 75 g glucose tolerance test (GTT), and a further blood sample taken after 2 h. Mononuclear cells were separated by centrifugation. Oxidative DNA damage was assessed by measuring 8-oxoguanine (8-OG) using a Biotrin OxyDNA test kit (Biotrin International, Dublin, Ireland), as we have previously described [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="11356" xml_f="11357" txt_i="5219" txt_f="5220">5</offsets></xref><offsets xml_i="11364" xml_f="11383" txt_i="5220" txt_f="5239">]. In brief, 1 × 10</offsets><sup><offsets xml_i="11388" xml_f="11390" txt_i="5239" txt_f="5241">6 </offsets></sup><offsets xml_i="11396" xml_f="12004" txt_i="5241" txt_f="5849">mononuclear cells were incubated with 1% paraformaldeyde for 15 min on ice, washed once with PBS, resuspended with 70% ethanol and kept at -20°C until analysed. Cells were washed with PBS then incubated with blocking buffer at 37°C for 1 h, washed twice, then incubated with FITC-labelled 8-OG probe for 1 h. The cells were washed twice and analysed by flow cytometry. Plasma insulin was measured using a human insulin-specific (no cross-reactivity with proinsulin) ELISA (Dako Cytomation, Ely, UK) and glucose by the glucose oxidase method. Plasma α-tocopherol was measured by HPLC as previously described [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="12035" xml_f="12036" txt_i="5849" txt_f="5850">3</offsets></xref><offsets xml_i="12043" xml_f="12045" txt_i="5850" txt_f="5852">].</offsets></p><p><offsets xml_i="12052" xml_f="12261" txt_i="5853" txt_f="6059">Data are expressed as mean and one standard error (SE) or 95% confidence intervals (CI). Differences between groups were analysed by paired or unpaired two-tailed t-tests and significance taken as p &lt; 0.05.</offsets></p></sec></sec><sec><title><offsets xml_i="12289" xml_f="12296" txt_i="6062" txt_f="6069">Results</offsets></title><p><offsets xml_i="12307" xml_f="12611" txt_i="6070" txt_f="6368">Both subject groups were matched for age, BMI and plasma insulin. However, by chance, the subjects allocated to the α-tocopherol treatment group had a significantly longer duration of diabetes (p &lt; 0.01) and a higher fasting plasma glucose concentration than the placebo treatment group (p &lt; 0.01).</offsets></p><sec><title><offsets xml_i="12627" xml_f="12640" txt_i="6369" txt_f="6382">Baseline data</offsets></title><p><offsets xml_i="12651" xml_f="12826" txt_i="6383" txt_f="6558">At the start of the study no differences were apparent in DNA damage, as assessed by 8-OG mean fluorescence intensity (MFI), in the mononuclear cells of the two groups (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="12858" xml_f="12859" txt_i="6558" txt_f="6559">1</offsets></xref><offsets xml_i="12866" xml_f="12868" txt_i="6559" txt_f="6561">).</offsets></p></sec><sec><title><offsets xml_i="12890" xml_f="12912" txt_i="6563" txt_f="6585">Day 0, post GTT (GTT1)</offsets></title><p><offsets xml_i="12923" xml_f="13047" txt_i="6586" txt_f="6710">No significant change in the level of DNA damage was detected following a GTT in the mononuclear cells of either group (fig </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13077" xml_f="13078" txt_i="6710" txt_f="6711">1</offsets></xref><offsets xml_i="13085" xml_f="13087" txt_i="6711" txt_f="6713">).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="13128" xml_f="13136" txt_i="6714" txt_f="6722">Figure 1</offsets></label><caption><p><bold><offsets xml_i="13162" xml_f="13422" txt_i="6722" txt_f="6982">Change in oxidative DNA damage, assessed by 8-oxoguanine fluorescence, in mononuclear cells isolated from type 2 diabetes patients before (GTT1) and after (GTT2) taking 1200 IU/day α-tocopherol or matched placebo for 4 weeks, following a glucose tolerance test</offsets></bold><offsets xml_i="13429" xml_f="13545" txt_i="6982" txt_f="7098">. Data shown are means; error bars represent 95% confidence intervals. AT: α-tocopherol, GTT: Glucose Tolerance Test</offsets></p></caption><graphic xlink:href="1475-2840-6-8-1"></graphic></fig></sec><sec><title><offsets xml_i="13631" xml_f="13653" txt_i="7100" txt_f="7122">Day 29, fasting sample</offsets></title><p><offsets xml_i="13664" xml_f="13900" txt_i="7123" txt_f="7356">Following the 4 week intervention, plasma α-tocopherol was significantly increased (p &lt; 0.01) in the α-tocopherol supplemented group but there was no significant change in mononuclear cell DNA damage in either treatment group (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="13932" xml_f="13933" txt_i="7356" txt_f="7357">1</offsets></xref><offsets xml_i="13940" xml_f="13942" txt_i="7357" txt_f="7359">).</offsets></p></sec><sec><title><offsets xml_i="13964" xml_f="13987" txt_i="7361" txt_f="7384">Day 29, post GTT (GTT2)</offsets></title><p><offsets xml_i="13998" xml_f="14201" txt_i="7385" txt_f="7588">There was a significant increase in DNA damage, assessed as a 13.6% (95% CI: 6.3–20.9) increase in 8-OG fluorescence, in the mononuclear cells from the α-tocopherol supplemented group following GTT (Fig </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14231" xml_f="14232" txt_i="7588" txt_f="7589">1</offsets></xref><offsets xml_i="14239" xml_f="14241" txt_i="7589" txt_f="7591">).</offsets></p><p><offsets xml_i="14248" xml_f="14468" txt_i="7592" txt_f="7812">A correlation (R = 0.649, p = 0.045), using simple linear regression, was observed between duration of diabetes and the percent change in 8-OG florescence following a GTT in the α-tocopherol supplemented group on day 29.</offsets></p></sec></sec><sec><title><offsets xml_i="14496" xml_f="14506" txt_i="7815" txt_f="7825">Discussion</offsets></title><p><offsets xml_i="14517" xml_f="14729" txt_i="7826" txt_f="8038">This study shows that after a relatively high dose of α-tocopherol for 4 weeks there was no change in oxidative DNA damage in mononuclear cells from subjects with type 2 diabetes, as we have reported previously [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="14760" xml_f="14761" txt_i="8038" txt_f="8039">3</offsets></xref><offsets xml_i="14768" xml_f="14838" txt_i="8039" txt_f="8109">]. However, following a glucose load with increased oxidative stress [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="14869" xml_f="14870" txt_i="8109" txt_f="8110">2</offsets></xref><offsets xml_i="14877" xml_f="15301" txt_i="8110" txt_f="8534">] the level of oxidative DNA damage increased significantly in α-tocopherol-supplemented type 2 diabetes patients which correlated with the duration of diabetes. This increase in oxidative DNA damage was not apparent in the placebo group. These data suggest that the high dose α-tocopherol treatment has primed a damaging response to acute hyperglycaemia in type 2 diabetes and may be related to the duration of the disease.</offsets></p><p><offsets xml_i="15308" xml_f="15416" txt_i="8535" txt_f="8643">The ability of α-tocopherol to act as a pro-oxidant and increase peroxidation of lipids has been long known </offsets><italic><offsets xml_i="15424" xml_f="15433" txt_i="8643" txt_f="8652">in vitro </offsets></italic><offsets xml_i="15442" xml_f="15443" txt_i="8652" txt_f="8653">[</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="15475" xml_f="15477" txt_i="8653" txt_f="8655">12</offsets></xref><offsets xml_i="15484" xml_f="15485" txt_i="8655" txt_f="8656">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="15517" xml_f="15519" txt_i="8656" txt_f="8658">13</offsets></xref><offsets xml_i="15526" xml_f="15692" txt_i="8658" txt_f="8824">] and increased DNA damage, attributed to α-tocopherol, in cultured cells has been described following an insult capable of generating reactive oxygen species (ROS) [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="15724" xml_f="15726" txt_i="8824" txt_f="8826">14</offsets></xref><offsets xml_i="15733" xml_f="15734" txt_i="8826" txt_f="8827">,</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="15766" xml_f="15768" txt_i="8827" txt_f="8829">15</offsets></xref><offsets xml_i="15775" xml_f="16116" txt_i="8829" txt_f="9170">]. Upon encountering ROS, α-tocopherol within lipid becomes oxidised forming its own radical, which requires co-antioxidants (e.g ascorbic acid) in order for the α-tocopherol to be regenerated. If the tocopherol radical is not eliminated there is an increase in lipid peroxidation, a process known as tocopherol-mediated peroxidation (TMP) [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="16148" xml_f="16150" txt_i="9170" txt_f="9172">16</offsets></xref><offsets xml_i="16157" xml_f="16243" txt_i="9172" txt_f="9258">]. These peroxidised lipids can produce a range of ROS which are able to damage DNA. H</offsets><sub><offsets xml_i="16248" xml_f="16249" txt_i="9258" txt_f="9259">2</offsets></sub><offsets xml_i="16255" xml_f="16256" txt_i="9259" txt_f="9260">O</offsets><sub><offsets xml_i="16261" xml_f="16262" txt_i="9260" txt_f="9261">2</offsets></sub><offsets xml_i="16268" xml_f="16448" txt_i="9261" txt_f="9441">, generated by TMP, while not damaging to DNA directly, is able to cross membranes and can react with transition metals (Fe, Cu) associated with DNA to generate hydroxyl radicals (</offsets><sup><offsets xml_i="16453" xml_f="16454" txt_i="9441" txt_f="9442">•</offsets></sup><offsets xml_i="16460" xml_f="16513" txt_i="9442" txt_f="9495">OH), by the Fenton reaction, to cause damage to DNA [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="16545" xml_f="16547" txt_i="9495" txt_f="9497">17</offsets></xref><offsets xml_i="16554" xml_f="16555" txt_i="9497" txt_f="9498">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="16587" xml_f="16589" txt_i="9498" txt_f="9500">18</offsets></xref><offsets xml_i="16596" xml_f="16711" txt_i="9500" txt_f="9615">]. In addition Cu,Zn-Superoxide dismutase has been reported to release free copper when it is oxidatively damaged [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="16743" xml_f="16745" txt_i="9615" txt_f="9617">19</offsets></xref><offsets xml_i="16752" xml_f="16753" txt_i="9617" txt_f="9618">,</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="16785" xml_f="16787" txt_i="9618" txt_f="9620">20</offsets></xref><offsets xml_i="16794" xml_f="16840" txt_i="9620" txt_f="9666">] which could lead to increased generation of </offsets><sup><offsets xml_i="16845" xml_f="16846" txt_i="9666" txt_f="9667">•</offsets></sup><offsets xml_i="16852" xml_f="16855" txt_i="9667" txt_f="9670">OH.</offsets></p><p><offsets xml_i="16862" xml_f="16952" txt_i="9671" txt_f="9761">Alpha-tocopherol has been reported to reduce γ-tocopherol concentrations in blood plasma [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="16984" xml_f="16986" txt_i="9761" txt_f="9763">21</offsets></xref><offsets xml_i="16993" xml_f="17133" txt_i="9763" txt_f="9903">] which could have a disadvantageous effect. Gamma-tocopherol is a potent scavenger of reactive nitrile species (RNS) such as nitric oxide (</offsets><sup><offsets xml_i="17138" xml_f="17139" txt_i="9903" txt_f="9904">•</offsets></sup><offsets xml_i="17145" xml_f="17176" txt_i="9904" txt_f="9935">NO) and peroxynitrate (ONOO-) [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="17208" xml_f="17210" txt_i="9935" txt_f="9937">22</offsets></xref><offsets xml_i="17217" xml_f="17444" txt_i="9937" txt_f="10164">], which may also damage biomolecules such as DNA. Peroxynitrate can also oxidise tetrahydrobioptrein (BH4), a co-factor of nitric oxide synthase (NOS) which causes uncoupling of NOS, resulting in the generation of superoxide (</offsets><sup><offsets xml_i="17449" xml_f="17450" txt_i="10164" txt_f="10165">•</offsets></sup><offsets xml_i="17456" xml_f="17457" txt_i="10165" txt_f="10166">O</offsets><sub><offsets xml_i="17462" xml_f="17463" txt_i="10166" txt_f="10167">2</offsets></sub><offsets xml_i="17469" xml_f="17496" txt_i="10167" txt_f="10194">) instead of nitric oxide (</offsets><sup><offsets xml_i="17501" xml_f="17502" txt_i="10194" txt_f="10195">•</offsets></sup><offsets xml_i="17508" xml_f="17513" txt_i="10195" txt_f="10200">NO) [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="17545" xml_f="17547" txt_i="10200" txt_f="10202">23</offsets></xref><offsets xml_i="17554" xml_f="17556" txt_i="10202" txt_f="10204">].</offsets></p><p><offsets xml_i="17563" xml_f="17718" txt_i="10205" txt_f="10360">The timing of ingestion of supplements relative to meal times has been shown to effect markers of inflammation and may have an effect on oxidative stress [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="17750" xml_f="17752" txt_i="10360" txt_f="10362">24</offsets></xref><offsets xml_i="17759" xml_f="18083" txt_i="10362" txt_f="10686">], but the effects were seen following a single dose of vitamin E, whilst subjects on the current study, although only instructed to take supplements daily, had sustained elevated plasma levels of α-tocopherol. Other factors which may affect the outcomes of vitamin E supplementation have been discussed in a recent review [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="18115" xml_f="18117" txt_i="10686" txt_f="10688">25</offsets></xref><offsets xml_i="18124" xml_f="18126" txt_i="10688" txt_f="10690">].</offsets></p><p><offsets xml_i="18133" xml_f="18309" txt_i="10691" txt_f="10867">High α-tocopherol intakes, at least without co-supplementation with other antioxidants such as vitamin C, which can reduce the α-tocopherol-induced lipid peroxidation observed </offsets><italic><offsets xml_i="18317" xml_f="18326" txt_i="10867" txt_f="10876">in vitro </offsets></italic><offsets xml_i="18335" xml_f="18336" txt_i="10876" txt_f="10877">[</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="18368" xml_f="18370" txt_i="10877" txt_f="10879">26</offsets></xref><offsets xml_i="18377" xml_f="18640" txt_i="10879" txt_f="11142">], may result in amplification of ROS generated in response to an increase in oxidative stress and increased RNS due to suppression of γ-tocopherol bioavailability. High dose vitamin C, used in EDTA chelation therapy, has been shown to have a pro-oxidant effect [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="18672" xml_f="18674" txt_i="11142" txt_f="11144">27</offsets></xref><offsets xml_i="18681" xml_f="18885" txt_i="11144" txt_f="11348">] and ceruloplasmin, a copper containing metalloenzyme, has been suggested to have a pro-oxidant effect in conditions of increased oxidative stress, such as diabetes, by the disruption of copper binding [</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="18917" xml_f="18919" txt_i="11348" txt_f="11350">28</offsets></xref><offsets xml_i="18926" xml_f="18946" txt_i="11350" txt_f="11370">]. A recent report [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="18978" xml_f="18980" txt_i="11370" txt_f="11372">29</offsets></xref><offsets xml_i="18987" xml_f="19306" txt_i="11372" txt_f="11691">] has suggested that the optimal serum concentration of α-tocopherol to reduce mortality from cardiovascular disease and cancer is 30–33 μmol/L. The mean plasma α-tocopherol concentration achieved in the supplemented group in this study was 66.5 μmol/L which may be high enough to be detrimental rather than beneficial.</offsets></p><p><offsets xml_i="19313" xml_f="19382" txt_i="11692" txt_f="11761">In a recent review of oxidative stress and antioxidant use, Johansen </offsets><italic><offsets xml_i="19390" xml_f="19396" txt_i="11761" txt_f="11767">et al </offsets></italic><offsets xml_i="19405" xml_f="19406" txt_i="11767" txt_f="11768">[</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="19438" xml_f="19440" txt_i="11768" txt_f="11770">30</offsets></xref><offsets xml_i="19447" xml_f="19877" txt_i="11770" txt_f="12200">] point out that most clinical trials conducted to date were not designed to specifically assess the effects of antioxidant use in diabetic patients, who experience a high level of oxidative stress, and that endpoints measured did not include specific markers of oxidative stress. However, in the current study we measured levels of 8-oxoguanine, a specific marker of oxidative DNA damage formed during free radical damage to DNA.</offsets></p></sec><sec><title><offsets xml_i="19899" xml_f="19910" txt_i="12202" txt_f="12213">Limitations</offsets></title><p><offsets xml_i="19921" xml_f="20697" txt_i="12214" txt_f="12990">This study does have some limitations. First, the patient numbers are too low to form definitive conclusions. Second, the patients are taking different pharmacological treatments, although only subjects who had never received gliclazide, antihypertensives or ACE inhibitors, which have anti-oxidant or anti-inflammatory properties, were included in this study. Thirdly, there is a mismatch in duration of diabetes and plasma glucose between the two groups, which could affect the results. However HbA1c was not significantly different between each group and neither group differed significantly in their fasting levels of mononuclear cell oxidative damage either at the beginning or end of the study, nor showed any significant change following a GTT prior to supplementation.</offsets></p></sec><sec><title><offsets xml_i="20719" xml_f="20729" txt_i="12992" txt_f="13002">Conclusion</offsets></title><p><offsets xml_i="20740" xml_f="21419" txt_i="13003" txt_f="13682">This report is to our knowledge the first to show a pro-oxidant action of α-tocopherol associated with increased DNA damage in patients with type 2 diabetes. Although this is a small sample these preliminary findings, given the observed correlation between duration of diabetes and increase in oxidative damage, suggest the possibility that high dose vitamin E is potentially more damaging in patients with longer duration of disease and needs further investigation. This data may be useful in interpreting negative vascular outcomes in large α-tocopherol intervention trials in subjects with increased basal levels of oxidative stress such as type 2 diabetes or atherosclerosis.</offsets></p></sec><sec><title><offsets xml_i="21441" xml_f="21454" txt_i="13684" txt_f="13697">Abbreviations</offsets></title><p><offsets xml_i="21465" xml_f="21483" txt_i="13698" txt_f="13716">8-OG: 8-oxoguanine</offsets></p><p><offsets xml_i="21490" xml_f="21506" txt_i="13717" txt_f="13733">AT: α-tocopherol</offsets></p><p><offsets xml_i="21513" xml_f="21540" txt_i="13734" txt_f="13761">GTT: Glucose tolerance test</offsets></p><p><offsets xml_i="21547" xml_f="21575" txt_i="13762" txt_f="13790">ROS: Reactive oxygen species</offsets></p><p><offsets xml_i="21582" xml_f="21611" txt_i="13791" txt_f="13820">RNS: Reactive nitrile species</offsets></p><p><offsets xml_i="21618" xml_f="21655" txt_i="13821" txt_f="13858">TMP: tocopherol-mediated peroxidation</offsets></p></sec><sec><title><offsets xml_i="21677" xml_f="21696" txt_i="13860" txt_f="13879">Competing interests</offsets></title><p><offsets xml_i="21707" xml_f="21767" txt_i="13880" txt_f="13940">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="21789" xml_f="21811" txt_i="13942" txt_f="13964">Authors' contributions</offsets></title><p><offsets xml_i="21822" xml_f="21887" txt_i="13965" txt_f="14030">MSW measured 8-oxoguanine fluorescence and drafted the manuscript</offsets></p><p><offsets xml_i="21894" xml_f="21937" txt_i="14031" txt_f="14074">MJS and DAH conceived and planned the study</offsets></p><p><offsets xml_i="21944" xml_f="21981" txt_i="14075" txt_f="14112">SS measured serum α-tocopherol levels</offsets></p><p><offsets xml_i="21988" xml_f="22014" txt_i="14113" txt_f="14139">JCH performed immunoassays</offsets></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was funded by a Core Strategic Grant from the Biotechnology &amp; Biological Sciences Research Council, U.K. and the Norwich &amp; Norfolk Diabetes Trust.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jay</surname><given-names>D</given-names></name><name><surname>Hitomi</surname><given-names>H</given-names></name><name><surname>Griendling</surname><given-names>KK</given-names></name></person-group><article-title>Oxidative stress and diabetic cardiovascular complications</article-title><source>Free Radical Biology and Medicine</source><year>2006</year><volume>40</volume><fpage>183</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">16413400</pub-id><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2005.06.018</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>MJ</given-names></name><name><surname>Gopaul</surname><given-names>N</given-names></name><name><surname>Davies</surname><given-names>IR</given-names></name><name><surname>Hughes</surname><given-names>DA</given-names></name><name><surname>Carrier</surname><given-names>MJ</given-names></name></person-group><article-title>Plasma F2 Isoprostanes: Direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">11874943</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M.J</surname><given-names>S</given-names></name><name><surname>S</surname><given-names>A</given-names></name><name><surname>S</surname><given-names>R</given-names></name><name><surname>G</surname><given-names>W</given-names></name><name><surname>I.R</surname><given-names>D</given-names></name><name><surname>DA</surname><given-names>H</given-names></name><name><surname>S</surname><given-names>S</given-names></name></person-group><article-title>Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in Type II diabetes: effects of a-tocopherol supplementation</article-title><source>Clinical Science</source><year>2001</year><volume>101</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">11524040</pub-id><pub-id pub-id-type="doi">10.1042/CS20010112</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dandona</surname><given-names>P</given-names></name><name><surname>Thusu</surname><given-names>K</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name><name><surname>Snyder</surname><given-names>B</given-names></name><name><surname>Makowski</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Nicotera</surname><given-names>T</given-names></name></person-group><article-title>Oxidative damage to DNA in diabetes mellitus</article-title><source>The Lancet</source><year>1996</year><volume>347</volume><fpage>444</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)90013-6</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>MJ</given-names></name><name><surname>Winterbone</surname><given-names>MS</given-names></name><name><surname>Hughes</surname><given-names>JC</given-names></name><name><surname>Dozio</surname><given-names>N</given-names></name><name><surname>Hughes</surname><given-names>DA</given-names></name></person-group><article-title>Monocyte Telomere Shortening and Oxidative DNA Damage in Type 2 Diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">16443874</pub-id><pub-id pub-id-type="doi">10.2337/diacare.29.02.06.dc05-1715</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><collab>The HOPE and HOPE-TOO Trial Investigators</collab></person-group><article-title>Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1338</fpage><lpage>1347</lpage><pub-id pub-id-type="pmid">15769967</pub-id><pub-id pub-id-type="doi">10.1001/jama.293.11.1338</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heart Protection Study Collaborative</surname><given-names>G</given-names></name></person-group><article-title>MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial</article-title><source>The Lancet</source><year>2002</year><volume>360</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)09328-5</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>ER</given-names><suffix>III</suffix></name><name><surname>Pastor-Barriuso</surname><given-names>R</given-names></name><name><surname>Dalal</surname><given-names>D</given-names></name><name><surname>Riemersma</surname><given-names>RA</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Guallar</surname><given-names>E</given-names></name></person-group><article-title>Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality</article-title><source>Ann Intern Med</source><year>2005</year><volume>142</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15537682</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D</given-names></name><name><surname>Witztum</surname><given-names>JL</given-names></name></person-group><article-title>Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>2107</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">11980692</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000014762.06201.06</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group><article-title>The antioxidant paradox</article-title><source>The Lancet</source><year>2000</year><volume>355</volume><fpage>1179</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02075-4</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sardas</surname><given-names>S</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><name><surname>Oztok</surname><given-names>U</given-names></name><name><surname>Cakir</surname><given-names>N</given-names></name><name><surname>Karakaya</surname><given-names>AE</given-names></name></person-group><article-title>Assessment of DNA strand breakage by comet assay in diabetic patients and the role of antioxidant supplementation</article-title><source>Mutation Research/Genetic Toxicology and Environmental Mutagenesis</source><year>2001</year><volume>490</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/S1383-5718(00)00157-1</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowry</surname><given-names>VM</given-names></name><name><surname>Igold</surname><given-names>S</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name></person-group><article-title>Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant.</article-title><source>Biochemical Journal</source><year>1992</year><volume>288</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">1463440</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santanam</surname><given-names>N</given-names></name><name><surname>Parthasarathy</surname><given-names>S</given-names></name></person-group><article-title>Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases.</article-title><source>J Clin Invest</source><year>1995</year><volume>95</volume><fpage>2594</fpage><lpage>2600</lpage><ext-link ext-link-type="uri" xlink:href="http://www.pubmedcentral.com/articlerender.fcgi?artid=295942"></ext-link><pub-id pub-id-type="pmid">7769102</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocentini</surname><given-names>S</given-names></name><name><surname>Guggiari</surname><given-names>M</given-names></name><name><surname>Rouillard</surname><given-names>D</given-names></name><name><surname>Surgis</surname><given-names>S</given-names></name></person-group><article-title>Exacerbating Effect of Vitamin E Supplementation on DNA Damage Induced in Cultured Human Normal Fibroblasts by UVA Radiation.</article-title><source>Photochemistry and Photobiology</source><year>2001</year><volume>73</volume><fpage>370</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">11332032</pub-id><pub-id pub-id-type="doi">10.1562/0031-8655(2001)073&lt;0370:EEOVES&gt;2.0.CO;2</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blasiak</surname><given-names>J</given-names></name><name><surname>Gloc</surname><given-names>E</given-names></name><name><surname>Wozniak</surname><given-names>K</given-names></name><name><surname>Mlynarski</surname><given-names>W</given-names></name><name><surname>Stolarska</surname><given-names>M</given-names></name><name><surname>Skorski</surname><given-names>T</given-names></name><name><surname>Majsterek</surname><given-names>I</given-names></name></person-group><article-title>Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine</article-title><source>Chemico-Biological Interactions</source><year>2002</year><volume>140</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12044557</pub-id><pub-id pub-id-type="doi">10.1016/S0009-2797(02)00012-1</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name></person-group><article-title>The ambivalence of vitamin E in atherogenesis</article-title><source>Trends in Biochemical Sciences</source><year>1999</year><volume>24</volume><fpage>219</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">10366846</pub-id><pub-id pub-id-type="doi">10.1016/S0968-0004(99)01404-8</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Burkitt</surname><given-names>MJ</given-names></name><name><surname>Milne</surname><given-names>L</given-names></name><name><surname>Kawanishi</surname><given-names>S</given-names></name></person-group><article-title>Tocopherol Induces Oxidative Damage to DNA in the Presence of Copper(II) Ions</article-title><source>Chem Res Toxicol</source><year>1998</year><volume>11</volume><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">9705746</pub-id><pub-id pub-id-type="doi">10.1021/tx970129v</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henle</surname><given-names>ES</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Gassmann</surname><given-names>W</given-names></name><name><surname>Linn</surname><given-names>S</given-names></name></person-group><article-title>Oxidative Damage to DNA Constituents by Iron-mediated Fenton Reactions. THE DEOXYGUANOSINE FAMILY</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>21177</fpage><lpage>21186</lpage><pub-id pub-id-type="pmid">8702888</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.35.21167</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Akaike</surname><given-names>T</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name></person-group><article-title>Hydroxyl radical production by H2O2 plus Cu,Zn-superoxide dismutase reflects the activity of free copper released from the oxidatively damaged enzyme</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><fpage>25371</fpage><lpage>25377</lpage><pub-id pub-id-type="pmid">1334093</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>SJ</given-names></name><name><surname>Koh</surname><given-names>YH</given-names></name><name><surname>Floyd</surname><given-names>RA</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name></person-group><article-title>Copper, zinc superoxide dismutase enhances DNA damage and mutagenicity induced by cysteine/iron</article-title><source>Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis</source><year>2000</year><volume>448</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/S0027-5107(00)00005-1</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>G</given-names></name></person-group><article-title>How an Increased Intake of Alpha-Tocopherol Can Suppress the Bioavailability of Gamma-Tocopherol </article-title><source>Nutrition Reviews</source><year>2006</year><volume>64</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">16808116</pub-id><pub-id pub-id-type="doi">10.1301/nr.2006.jun.295-299</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Christen</surname><given-names>S</given-names></name><name><surname>Shigenaga</surname><given-names>MK</given-names></name><name><surname>Ames</surname><given-names>BN</given-names></name></person-group><article-title>{gamma}-Tocopherol, the major form of vitamin E in the US diet, deserves more attention</article-title><source>Am J Clin Nutr</source><year>2001</year><volume>74</volume><fpage>714</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">11722951</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laursen</surname><given-names>JB</given-names></name><name><surname>Somers</surname><given-names>M</given-names></name><name><surname>Kurz</surname><given-names>S</given-names></name><name><surname>McCann</surname><given-names>L</given-names></name><name><surname>Warnholtz</surname><given-names>A</given-names></name><name><surname>Freeman</surname><given-names>BA</given-names></name><name><surname>Tarpey</surname><given-names>M</given-names></name><name><surname>Fukai</surname><given-names>T</given-names></name><name><surname>Harrison</surname><given-names>DG</given-names></name></person-group><article-title>Endothelial Regulation of Vasomotion in ApoE-Deficient Mice : Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin</article-title><source>Circulation</source><year>2001</year><volume>103</volume><fpage>1282</fpage><lpage>1288</lpage><pub-id pub-id-type="pmid">11238274</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>MF</given-names></name><name><surname>Schade</surname><given-names>DS</given-names></name></person-group><article-title>Timing of Antioxidant Vitamin Ingestion Alters Postprandial Proatherogenic Serum Markers</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12821556</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000074221.68903.77</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>I</given-names></name><name><surname>de Serna</surname><given-names>DG</given-names></name><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Schade</surname><given-names>DS</given-names></name></person-group><article-title>Vitamin E in Humans: An Explanation of Clincal Trial Failure.</article-title><source>Endocrine Practice</source><year>2007</year><volume>12</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">17002935</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bowry</surname><given-names>VW</given-names></name><name><surname>Stocker</surname><given-names>R</given-names></name></person-group><article-title>Tocopherol-mediated peroxidation. The prooxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein</article-title><source>Journal of the American Chemical Society</source><year>1993</year><volume>115</volume><fpage>6029</fpage><lpage>6044</lpage><pub-id pub-id-type="doi">10.1021/ja00067a019</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hininger</surname><given-names>I</given-names></name><name><surname>Waters</surname><given-names>R</given-names></name><name><surname>Osman</surname><given-names>M</given-names></name><name><surname>Garrel</surname><given-names>C</given-names></name><name><surname>Fernholz</surname><given-names>K</given-names></name><name><surname>Roussel</surname><given-names>AM</given-names></name><name><surname>Anderson</surname><given-names>RA</given-names></name></person-group><article-title>Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy</article-title><source>Free Radical Biology and Medicine</source><year>2005</year><volume>38</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">15917185</pub-id><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2005.02.016</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shukla</surname><given-names>N</given-names></name><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Masters</surname><given-names>J</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><name><surname>Jeremy</surname><given-names>JY</given-names></name></person-group><article-title>Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?</article-title><source>Atherosclerosis</source><year>2006</year><volume>187</volume><fpage>238</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">16412446</pub-id><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2005.11.035</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>ME</given-names></name><name><surname>Lawson</surname><given-names>KA</given-names></name><name><surname>Weinstein</surname><given-names>SJ</given-names></name><name><surname>Pietinen</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name></person-group><article-title>Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>84</volume><fpage>1200</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">17093175</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Harris</surname><given-names>AK</given-names></name><name><surname>Rychly</surname><given-names>DJ</given-names></name><name><surname>Adviye</surname><given-names>E</given-names></name></person-group><article-title>Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice</article-title><source>Cardiovascular Diabetology</source><year>2005</year><volume>4:5</volume></citation></ref></ref-list></back></article>